Stryker Co. (NYSE:SYK) Position Trimmed by Van Cleef Asset Management Inc

Van Cleef Asset Management Inc trimmed its stake in Stryker Co. (NYSE:SYK) by 0.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 46,738 shares of the medical technology company’s stock after selling 108 shares during the quarter. Stryker accounts for 1.8% of Van Cleef Asset Management Inc’s portfolio, making the stock its 14th largest position. Van Cleef Asset Management Inc’s holdings in Stryker were worth $16,828,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Dunhill Financial LLC increased its stake in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares during the last quarter. Centricity Wealth Management LLC acquired a new stake in shares of Stryker during the 4th quarter valued at about $30,000. BankPlus Trust Department bought a new position in shares of Stryker during the 4th quarter valued at $33,000. Darwin Wealth Management LLC acquired a new stake in shares of Stryker in the 3rd quarter valued at $36,000. Finally, Activest Wealth Management bought a new stake in shares of Stryker during the 4th quarter worth about $36,000. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

NYSE SYK opened at $389.10 on Friday. The stock has a market cap of $148.47 billion, a P/E ratio of 50.14, a PEG ratio of 2.93 and a beta of 0.96. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company’s 50-day simple moving average is $380.06 and its 200 day simple moving average is $370.50.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the firm posted $3.46 earnings per share. As a group, research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is currently 43.30%.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. JMP Securities reissued a “market perform” rating on shares of Stryker in a research note on Tuesday, February 18th. Royal Bank of Canada lifted their price target on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research report on Wednesday, January 29th. Truist Financial upped their price objective on shares of Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a report on Thursday, January 30th. Wells Fargo & Company lifted their target price on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Finally, Canaccord Genuity Group upped their price target on shares of Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $422.15.

Insider Buying and Selling at Stryker

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. The trade was a 14.16 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.